Inogen, Inc. — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing also reports fourth-quarter results. Unless otherwise noted, financial amounts are in U.S. dollars.
Business context
Inogen develops, manufactures and markets portable oxygen concentrators and related products, including the Inogen One G2 and G3 and the Inogen At Home stationary concentrator. Its U.S. business combines direct-to-consumer equipment sales and Medicare or insurance rentals with business-to-business sales; international sales are primarily through distributors and large provider accounts. Inogen reported serving more than 127,000 patients through direct sales or rentals since adopting its direct-to-consumer model.
Financial performance and liquidity
| Metric | FY2015 | FY2014 | Change |
|---|---|---|---|
| Total revenue | $159.0 million | $112.5 million | +41.3% |
| Sales revenue | $113.6 million | $73.1 million | +55.4% |
| Rental revenue | $45.4 million | $39.4 million | +15.1% |
| Gross profit | $76.3 million | $55.5 million | +37.4% |
| Operating income | $15.1 million | $10.5 million | +43.2% |
| Net income | $11.6 million | $6.8 million | +69.7% |
| Diluted EPS | $0.56 | $0.30 | — |
| Operating cash flow | $38.2 million | $15.7 million | +143.1% |
Gross margin was 48.0%, down from 49.3%. Sales gross margin declined to 45.8% from 47.1%, largely because sales shifted toward lower-margin business-to-business channels and average revenue per unit fell 8.8%; lower unit costs partly offset the pressure. Rental gross margin was 53.3%, compared with 53.5%.
Systems sold rose to 56,600 from 33,200, and rental patients increased to 32,800 from 28,400. International revenue was $35.3 million, up from $24.4 million, representing about 22% of FY2015 revenue. Medicare accounted for 21.0% of total revenue, down from 26.5% in FY2014, and 73.7% of rental revenue.
At year-end, cash and cash equivalents were $66.1 million and short-term investments were $16.8 million; working capital was $92.8 million. Total indebtedness was $0.3 million, consisting of patent-related debt. The company had a $15 million revolving credit facility with no borrowings outstanding and reported compliance with its covenants. Operating cash flow was $38.2 million; investing cash outflow was $29.3 million, including investment purchases and $10.2 million for rental assets. Management said available liquidity and expected cash generation should fund requirements for at least 12 months.
Fourth quarter: Revenue was $40.4 million, gross profit $20.0 million and net income $3.9 million, versus $29.1 million, $13.8 million and $1.5 million, respectively, in Q4 2014.
Material changes and notable items
- Sales growth reflected higher system volume, expanded sales staffing and marketing, business-to-business demand, and the first full year of Inogen At Home sales. The upgraded G3 launched in December 2015.
- Sales and marketing expense rose 30.2% to $31.4 million; general and administrative expense rose 43.0% to $25.7 million. G&A included $1.8 million of audit committee investigation and class-action-related costs, which the company said were concluded in Q2 2015.
- Operating cash flow improved substantially, although working capital absorbed cash, including from accounts receivable and inventory growth. The receivables allowance as a share of gross receivables increased to 23.6% from 16.2%; management attributed this to patient responsibility balances, held/unbilled receivables and aging Medicare receivables.
- FY2014 net income included a substantial tax benefit from releasing valuation allowances; FY2015’s higher net income therefore should be assessed alongside tax effects. FY2015 diluted EPS was $0.56 versus $0.30 in FY2014.
- The company disclosed a material weakness in revenue documentation controls identified in prior filings and stated it was remediated by December 31, 2015. Management concluded controls were effective; the external auditor did not attest to internal controls because Inogen was an emerging growth company.
Outlook, risks and contingencies
- Reimbursement outlook: Management estimated nationalization of Medicare competitive bidding would reduce FY2016 total revenue by approximately 2.5%–3.5%. The company expected further rate changes from competitive bidding, including round-two re-compete pricing scheduled to take effect July 1, 2016; final pricing was not yet announced in the filing. Management also expected rental revenue per patient to decline.
- Product plans: The company expected to commercialize its fourth-generation portable concentrator, the Inogen One G4, in Q2 2016, describing it as smaller, lighter and less expensive to manufacture. No full-year revenue or earnings guidance was provided.
- Key business risks: Dependence on Medicare and other reimbursement programs; payment reductions, prior authorization and capped rental economics; reimbursement audits and collection delays; competitive pressure; reliance on some single-source suppliers; manufacturing disruption; product liability and regulatory compliance; foreign currency exposure; and protection of intellectual property.
- Legal matters: A 2015 securities class action was voluntarily dismissed and the case closed. A separate SDGIP lawsuit alleges patent infringement, trade-secret misappropriation and breach of contract, seeking unspecified damages and injunctive relief; Inogen denies the claims and is contesting them. Its patent litigation against Inova Labs remained stayed while reexamination of one patent was unresolved.
- Other exposures: The filing identifies potential impacts from proposed federal budget measures and Medicaid reimbursement changes, and describes contingent indemnification obligations for which liabilities were not recorded because amounts could not be reasonably estimated.
Important facts for investors to verify
- Actual impact of 2016 Medicare rate changes and competitive bidding re-compete pricing on rental revenue, margins and patient acquisition.
- Whether sales volume and growth persist as business-to-business sales increase and sales margins face mix and pricing pressure.
- Collections, aging and reserve adequacy for receivables, especially Medicare, held/unbilled balances and patient responsibility amounts.
- Execution, timing, manufacturing readiness and market acceptance of the planned G4 launch.
- Outcome and potential financial exposure from SDGIP litigation, and any developments in the Inova Labs patent proceedings.
- Sustained effectiveness of remediated revenue controls and continued compliance with Medicare documentation and billing requirements.